Product Name	KEYTRUDA
Active substance	Pembrolizumab
Indication and conditions of use	Medical Need Program with KEYTRUDA for the First-Line treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in adults whose tumors express PD-L1 with a ≥50% tumor proportion score (TPS) with no EGFR- or ALK- positive tumor mutations. *form:* Concentrate for solution for infusion. *dosage:* 25 mg/mL concentrate for solution for infusion. One vial of 4 mL of concentrate contains 100 mg of pembrolizumab. Each mL of concentrate contains 25 mg of pembrolizumab. *route of administration:* KEYTRUDA must be administered by intravenous infusion over 30 minutes. KEYTRUDA must not be administered as an intravenous push or bolus injection. *posology:* The recommended dose of KEYTRUDA is 200 mg for NSCLC that has not been previously treated with chemotherapy.
Conditions, delays and further rules for participation of patients	**Inclusion criteria** A patient must meet all of the following criteria to be eligible to participate in the MNP: 1) Patient with a diagnosis of histologically or cytologically confirmed stage IV NSCLC whose tumors express PD-L1 with a ≥50% tumor proportion score (TPS), with no sensitizing EGFR mutations or ALK translocations, with no previous systemic therapy for metastatic disease, that cannot be satisfactorily treated with the approved and commercially available alternative treatments because of efficacy and/or safety issue(s) 2) Patient has had measurable disease based on RECIST 1.1 as determined by the site. 3) Patient is ≥18 years of age at signing of informed consent/assent. 4) Patient with an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. (See annex 13.1) 5) If female patient of child bearing potential : negative urine or serum pregnancy test. 6) Women of childbearing potential are willing to use effective contraception during treatment with pembrolizumab and for at least 4 months after the last dose of pembrolizumab

	7) Patient has adequate organ function defined by the following hematological and biochemical criteria: • AST (SGOT) and ALT (SGPT) ≤1.5XULN Alkaline phosphatase ≤2.5 XULN. • Total bilirubin ≤ULN • Creatinine OR calculated creatinine clearance (CrCl)a (GFR can also be used in place of creatinine or CrCl) ≤1.5X upper limit of normal (ULN) OR ≥60 mL/min for subjects with creatinine levels >1.5X institutional ULN • Absolute neutrophil count ≥1,500 /mcL • Platelets ≥100,000 /mcL • Hemoglobin ≥9 g/dL or ≥ 5.6 mmol/L 8) Patients should have been clearly and completely informed by the requesting physician and provided written consent, before the start of the treatment **Exclusion criteria** A patient meeting any of the following criteria is not eligible to participate in the MNP: 1) The patient is eligible for a clinical trial running with Keytruda and/or a clinical trial running in the indication of the program with another molecule. 2) The patient has sensitizing mutations of EGFR and/or translocations of ALK who are currently receiving or eligible for treatment for this mutations. 3) Tumor specimen was not evaluable for PD-L1 expression by the central laboratory or less than 50 %. 4) Patient has received prior systemic cytotoxic chemotherapy, biological therapy, OR major surgery within 3 weeks of the first dose of trial treatment; received thoracic radiation therapy of >30 Gy within 6 months of the first dose of trial treatment. 5) Patient has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). 6) History of clinically severe (e.g., requires chronic immunosuppressive therapy during the last two years) autoimmune disease (e.g., ulcerative colitis, lupus) or currently active autoimmune disease. 7) History of interstitial lung disease (ILD) OR had a history of pneumonitis that has required oral or IV steroids. History of human immunodeficiency virus (HIV), active hepatitis B or hepatitis C or tuberculosis. 8) Patient was receiving systemic steroid therapy <3 days prior to the first dose of trial treatment or receiving any other form of immunosuppressive

	medication (corticosteroid use on study for management of ECIs, as pre-medication for the control chemotherapies, and/or a premedication for IV contrast allergies/reactions were allowed). Subjects who are receiving daily steroid replacement therapy served as an exception to this rule. Daily prednisone at doses of 5 to 7.5 mg was an example of replacement therapy. Equivalent hydrocortisone doses are also permitted if administered as a replacement therapy. 9) Patient is expected to require any other form of systemic antineoplastic therapy while receiving Keytruda 10) The patient has active central nervous system metastases and/or carcinomatous meningitis. (NOTE: Patients with previously treated brain metastases may participate provided they are clinically stable. Patients with untreated brain metastasis will be excluded.) 11) Condition (including but not limited to psychiatric or substance abuse disorders) which would interfere with patient compliance or safety. 12) Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of treatment with Keytruda. 13) The patient is unable to voluntarily agree to participate by signed informed consent/assent. 14) Active infection requiring systemic therapy. 15) Has received a live virus vaccine within 30 days of planned start of therapy. The patient is not eligible for a clinical trial running with Keytruda and/or a clinical trial running in the envisaged indication of this program. Patients should have been clearly and completely informed by the requesting physician and provided written consent, before the start of the treatment. <u>Specific timelines on the treatment of the request by the treating physician and other information that might be relevant for a patient</u> Treatment request will be answered within 7 working days by the treating physician

Duration of the program	The inclusion of patients will start the day after the EMA approval is obtained in this indication' Keytruda will be provided free of charge by MSD on an individual patient basis following the criteria stated in this program until the product will be commercially available and reimbursed in Belgium or until, in the clinical judgement of the treating physician, the patient is not longer benefiting from continuation of the treatment (intolerance or progressive disease), whichever is sooner. Or for a maximum period of 9 months after EMA approval.
Conditions of distribution	Patients will have access to the medicinal product only at the hospital where the prescribing physician is working. Drug will be delivered to the hospital pharmacy of the requesting physician within 5 working days after approval of initial request or after request for resupply.
Responsible of the program	**MSD BELGIUM BVBA/SPRL** Clos du Lynx, 5 1200 – Bruxelles with contact person Mrs Katrien Willaert Associate Director Medical Affairs, Oncology msdbelux-medicalaffairs@NorthAmerica.msx.merck.com
Modalities for the disposal	Any unused medication needs to be destroyed in an appropriate facility as soon as possible after the patient's discontinuation from the Medical Need Program. The medication delivered for an individual patient request in the context of the Medical Need Program can only be used for that particular patient.
The information for registration of suspected unexpected serious adverse reactions	Like all medicines, this medicine can cause side effects, although not everybody gets them. When you get KEYTRUDA, you can have some serious side effects. The following side effects have been reported in clinical trials: **Very common (may affect more than 1 in 10 people)** - diarrhoea; nausea - itching; skin rash - joint pain - feeling tired **Common (may affect up to 1 in 10 people)** - decrease in the number of red blood cells - thyroid gland problems; hot flush - feeling less hungry - headache; dizziness; change in your sense of taste - inflammation of the lungs; shortness of breath; cough - inflammation of the intestines; dry mouth

	- dry eye - stomach pain; constipation; vomiting - red raised rash sometimes with blisters; patches of skin which have lost colour; dry, itchy skin - muscle pain, aches or tenderness; pain in the muscles and bones; pain in arms or legs; joint pain with swelling - swelling; unusual tiredness or weakness; chills; flu-like illness; fever - increased liver enzyme levels in the blood; abnormal kidney function test - reaction related to the infusion of the medicine **Uncommon (may affect up to 1 in 100 people)** - a decreased number of white blood cells (neutrophils, leukocytes, lymphocytes and eosinophils); decrease in the number of platelets (bruising or bleeding more easily) - inflammation of the pituitary gland situated at the base of the brain; decreased secretion of hormones produced by the adrenal glands; inflammation of the thyroid - type 1 diabetes; decreased sodium, potassium and calcium in the blood - trouble sleeping - seizure; lack of energy; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs - inflammation of the eyes; eye pain, irritation, itchiness or redness; uncomfortable sensitivity to light; seeing spots - high blood pressure - inflammation of the pancreas - inflammation of the liver - thickened, sometimes scaly, skin growth; hair loss; inflammation of the skin; acne-like skin problem; hair colour changes; small skin bumps, lumps or sores - inflammation of the sheath that surrounds tendons - inflammation of the kidneys - increased level of amylase, an enzyme that breaks down starch; increased calcium in the blood **Rare (may affect up to 1 in 1000 people)** - inflammation response against platelets or red blood cells - a temporary inflammation of the nerves that cause pain, weakness, and paralysis in the extremities; a condition in which the muscles become weak and tire easily - a hole in the small intestines - tender red bumps under the skin **Reporting of side effects** If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Agence fédérale des médicaments et des produits de santé. Division Vigilance. EUROSTATION II. Place Victor Horta, 40/ 40. B-1060 Bruxelles. (Site internet:

	www.afmps.be , e-mail: patientinfo@fagg-afmps.be . By reporting side effects you can help provide more information on the safety of this medicine.